

**EUPRAXIA PHARMACEUTICALS INC.
MAJORITY VOTING POLICY**

The Board of Directors of Eupraxia Pharmaceuticals Inc. (the “**Company**”) believes that each of its members should carry the confidence and support of its shareholders and is committed to upholding high standards in corporate governance.

Forms of proxy for the vote at a shareholders’ meeting where directors are to be elected will enable the shareholder to vote in favour of, or to withhold from voting for, each nominee on an individual basis. At the meeting, the Chair will call for a vote by ballot and the scrutineers will record, with respect to each nominee, the number of shares in his or her favour and the number of shares withheld from voting. Prior to receiving the scrutineer’s report on the ballot, the Chair may announce the vote result based on the number of proxies received by the Company. At the conclusion of the meeting, the final scrutineer’s report on the ballot must be filed on SEDAR.

If, in an uncontested election of Directors, the number of shares “withheld” for any nominee exceeds the number of shares voted “for” the nominee, then, notwithstanding that such Director was duly elected as a matter of corporate law, he or she shall, immediately upon receipt the final scrutineer’s report on the ballot, tender his or her written resignation to the Chair of the Board. An “uncontested election” means an election where the number of nominees for Director is not greater than the number of Directors to be elected. The Nominating and Corporate Governance Committee will consider such offer of resignation and will make a recommendation to the Board concerning the acceptance or rejection of the resignation. In its deliberations, the Nominating and Corporate Governance Committee will consider all factors deemed relevant. The Board will take formal action on the Nominating and Corporate Governance Committee’s recommendation no later than 90 days following the date of the applicable shareholders’ meeting and will announce its decision via press release and provide a copy of such press release to the Toronto Stock Exchange. Absent exceptional circumstances, the Board will be expected to accept the resignation which will be effective on such date. If the Board declines to accept the resignation, it will include in the press release the reason or reasons for its decision.

No Director who is required to tender his or her resignation shall participate in the Nominating and Corporate Governance Committee’s deliberations or recommendations or in the Board’s deliberations or determination respecting such matters. In the event any Director fails to tender his or her written resignation when required to do so under this Policy, such Director shall not be put forward by the Board as a nominee at the next shareholders’ meeting where directors are to be elected.

If a resignation is accepted by the Board, and subject to any corporate law restrictions, the Board may leave any resulting vacancy unfilled until the next annual general meeting, or may appoint a new Director to fill the vacancy who the Board considers to merit the confidence of the shareholders, or may call a special meeting of shareholders at which there will be presented a management slate to fill the vacant position or positions.

* * * * *

Dated: March 2, 2021